Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:adjuvantType |
TLR9 agonist
|
| gptkbp:alternativeTo |
gptkb:Recombivax_HB
gptkb:Engerix-B |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J07BC01
|
| gptkbp:brand |
gptkb:Heplisav-B
|
| gptkbp:contains |
CpG 1018 adjuvant
recombinant hepatitis B surface antigen |
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:dosingSchedule |
2 doses, 1 month apart
|
| https://www.w3.org/2000/01/rdf-schema#label |
Heplisav-B
|
| gptkbp:indication |
adults 18 years and older
|
| gptkbp:manufacturer |
gptkb:Dynavax_Technologies
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:storage |
2–8°C
|
| gptkbp:usedFor |
hepatitis B prevention
|
| gptkbp:bfsParent |
gptkb:Hepatitis_B_vaccine
gptkb:Hepatitis_B_Vaccine |
| gptkbp:bfsLayer |
6
|